Financial Data and Key Metrics Changes - Agilent reported revenue of $1.701 billion for Q4 2024, reflecting a 1% increase year-over-year and flat core growth, with a sequential improvement of over 400 basis points from Q3 [14][35] - The company's earnings per share (EPS) for Q4 was $1.46, up 6% from the previous year, exceeding expectations [45] - Gross margin was 55.1%, down 70 basis points year-over-year, while operating margin was 27.4% [44] Business Line Data and Key Metrics Changes - Life Sciences and Applied Markets Group reported $833 million in revenue, a 1% decline due to constrained instrument volumes, although consumables grew mid-single digits [36] - Agilent CrossLab Group delivered revenue of $426 million, up 5%, with growth in every market except China [37] - Diagnostics and Genomics Group posted $442 million in revenue, representing a 3% decline, with solid growth in pathology offset by softness in NASD and cell-analysis instruments [39] Market Data and Key Metrics Changes - The largest end market, Pharma, declined 1%, with biopharma down mid-single digits and small molecule growing low-single digits [40] - Revenue in Chemicals and Advanced Materials grew 1%, driven by the semiconductor market [41] - Environmental and Forensics declined 6%, but PFAS solutions grew over 40% in Q4 [42] Company Strategy and Development Direction - Agilent announced a new market-focused organizational structure aimed at becoming more customer-centric and agile, part of its Ignite transformation program [16][31] - The company is focused on key growth vectors such as biopharma, PFAS, and Advanced Materials, with a commitment to innovation and customer-first strategies [30][32] - The acquisition of BIOVECTRA is expected to enhance Agilent's capabilities in therapeutic programs and expand its portfolio of CDMO services [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about steady market recovery and expects improvement throughout fiscal 2025, with a return to more traditional growth levels in the second half of the year [50][51] - The company anticipates modest growth in the Americas and Europe, with a conservative approach to revenue timing associated with stimulus in China [53] - Management highlighted the importance of the Ignite transformation in driving revenue growth and margin expansion [31][56] Other Important Information - Agilent achieved over $1 billion in digital orders for the first time in fiscal 2024, reflecting investments in its digital ecosystem [30] - The company returned over $400 million to shareholders in Q4, consisting of share repurchases and dividends [47] - Agilent was named Number 11 among Fortune's World's Best Workplaces 2024, highlighting its strong company culture [62] Q&A Session Summary Question: Instrument growth and replacement cycle expectations - Management noted a steady recovery in instruments with a book-to-bill ratio greater than one, indicating a positive outlook for the replacement cycle [68][69] Question: Expectations for China and stimulus orders - Management reported better-than-expected performance in China, with expectations for continued improvement and additional stimulus orders anticipated in Q1 [72][73] Question: Growth drivers in Diagnostics and Genomics Group - Management highlighted strong growth in pathology and a positive outlook for genomics, driven by differentiated value propositions and product traction [80][82] Question: Impact of tariffs on business - Management has diversified its supply chain to mitigate tariff impacts, estimating current exposure to be manageable [88][89] Question: Segment expectations for fiscal 2025 - Management provided guidance for low to mid-single-digit growth across various segments, with a focus on recovery in diagnostics and clinical markets [108][109]

Agilent Technologies (A) reported $1.7 billion in revenue for the quarter ended October 2024, representing a year-over-year increase of 0.8%. EPS of $1.46 for the same period compares to $1.38 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.67 billion, representing a surprise of +1.65%. The company delivered an EPS surprise of +3.55%, with the consensus EPS estimate being $1.41.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...

Agilent Technologies (A) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.41 per share. This compares to earnings of $1.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.55%. A quarter ago, it was expected that this scientific instrument maker would post earnings of $1.25 per share when it actually produced earnings of $1.32, delivering a surprise of 5.60%.Over the last four qu ...

[Financial Highlights](index=1&type=section&id=Financial%20Highlights) Agilent reported solid Q4 and full fiscal year 2024 financial results, driven by strong execution and a new market-based strategy Q4 Fiscal Year 2024 Financial Highlights | Metric | Q4 2024 | Q4 2023 | Change | Core Change | | :--- | :--- | :--- | :--- | :--- | | Revenue | $1.70B | $1.69B | +0.8% | -0.3% | | GAAP Net Income | $351M | $475M | -26.1% | N/A | | GAAP EPS | $1.22 | $1.62 | -24.7% | N/A | | Non-GAAP Net Income | $418M | $404M | +3.5% | N/A | | Non-GAAP EPS | $1.46 | $1.38 | +5.8% | N/A | Full Fiscal Year 2024 Financial Highlights | Metric | FY 2024 | FY 2023 | Change | Core Change | | :--- | :--- | :--- | :--- | :--- | | Revenue | $6.51B | $6.83B | -4.7% | -4.7% | | GAAP Net Income | $1.289B | $1.240B | +4.0% | N/A | | GAAP EPS | $4.43 | $4.19 | +5.7% | N/A | | Non-GAAP Net Income | $1.539B | $1.609B | -4.3% | N/A | | Non-GAAP EPS | $5.29 | $5.44 | -2.8% | N/A | - **CEO Padraig McDonnell** stated that the team delivered solid Q4 results as markets continued to recover, emphasizing that the new market-based, customer-first strategy and organizational structure will position the company for more growth opportunities as the market improves[6](index=6&type=chunk) [Segment Performance](index=2&type=section&id=Segment%20Performance) Agilent CrossLab Group (ACG) showed consistent growth in Q4 and full fiscal year 2024, while other segments experienced declines Life Sciences and Applied Markets Group (LSAG) Performance | Period | Revenue | Reported Change | Core Change | Operating Margin | | :--- | :--- | :--- | :--- | :--- | | Q4 2024 | $833M | -1% | -1% | 28.0% | | FY 2024 | $3.22B | -8% | -8% | 27.3% | Diagnostics and Genomics Group (DGG) Performance | Period | Revenue | Reported Change | Core Change | Operating Margin | | :--- | :--- | :--- | :--- | :--- | | Q4 2024 | $442M | -1% | -3% | 21.2% | | FY 2024 | $1.65B | -6% | -6% | 19.4% | Agilent CrossLab Group (ACG) Performance | Period | Revenue | Reported Change | Core Change | Operating Margin | | :--- | :--- | :--- | :--- | :--- | | Q4 2024 | $426M | +5% | +5% | 32.6% | | FY 2024 | $1.64B | +5% | +5% | 31.9% | [Financial Outlook](index=1&type=section&id=Full%20Year%202025%20and%20First-Quarter%20Outlook) Agilent provided its fiscal year 2025 and first-quarter 2025 financial guidance, projecting modest revenue and EPS growth Fiscal Year 2025 Outlook | Metric | Guidance Range | | :--- | :--- | | Revenue | $6.790B - $6.870B | | Reported Revenue Growth | +4.3% to +5.5% | | Core Revenue Growth | +2.5% to +3.5% | | Non-GAAP EPS | $5.54 - $5.61 | First-Quarter Fiscal Year 2025 Outlook | Metric | Guidance Range | | :--- | :--- | | Revenue | $1.650B - $1.680B | | Reported Revenue Growth | -0.5% to +1.3% | | Core Revenue Growth | -2.0% to -0.2% | | Non-GAAP EPS | $1.25 - $1.28 | [Corporate Developments](index=3&type=section&id=Corporate%20Developments) Agilent announced a new organizational structure as part of its transformation to become more agile and customer-centric - The company announced a new organizational structure to become nimbler and more customer-centric[15](index=15&type=chunk) - More information about the company's evolved market-focused strategy and transformation will be shared at its Investor Day in New York City on Dec. 17, 2024[15](index=15&type=chunk) - Management will host a conference call for investors to discuss Q4 2024 financial results, with a replay available on the company's website for 90 days[14](index=14&type=chunk) [Consolidated Financial Statements (Preliminary & Unaudited)](index=5&type=section&id=Consolidated%20Financial%20Statements) Preliminary financial statements detail the company's balance sheet, income, and cash flow, alongside reconciliations for non-GAAP measures and core revenue [Condensed Consolidated Statement of Operations](index=5&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENT%20OF%20OPERATIONS) The statement of operations details fiscal year 2024 revenue, income from operations, and GAAP net income, showing a slight increase in profitability despite lower revenue Fiscal Year Ended October 31 (In millions, except per share data) | Account | 2024 | 2023 | | :--- | :--- | :--- | | Net revenue | $6,510 | $6,833 | | Income from operations | $1,488 | $1,350 | | Net income | $1,289 | $1,240 | | Diluted EPS | $4.43 | $4.19 | [Condensed Consolidated Balance Sheet](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEET) The balance sheet shows an increase in total assets and liabilities as of October 31, 2024, with stable stockholders' equity Balance Sheet Highlights as of October 31 (In millions) | Account | 2024 | 2023 | | :--- | :--- | :--- | | Total current assets | $3,959 | $4,186 | | Total assets | $11,846 | $10,763 | | Total current liabilities | $1,895 | $1,603 | | Long-term debt | $3,345 | $2,735 | | Total liabilities | $5,948 | $4,918 | | Total stockholders' equity | $5,898 | $5,845 | [Condensed Consolidated Statement of Cash Flows](index=7&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENT%20OF%20CASH%20FLOWS) Cash flow statement indicates strong operating cash flow, increased investing activities due to acquisitions, and significant cash used in financing for repurchases and dividends Cash Flow Summary for Fiscal Year Ended October 31 (In millions) | Activity | 2024 | 2023 | | :--- | :--- | :--- | | Net cash provided by operating activities | $1,751 | $1,772 | | Net cash used in investing activities | $(1,258) | $(310) | | Net cash used in financing activities | $(752) | $(930) | | Net (decrease) in cash | $(261) | $537 | | Cash at end of period | $1,332 | $1,593 | [Non-GAAP Reconciliations](index=10&type=section&id=NON-GAAP%20NET%20INCOME%20AND%20DILUTED%20EPS%20RECONCILIATIONS) Non-GAAP reconciliations provide adjusted financial metrics, excluding specific items like intangible amortization and restructuring costs, to offer a clearer view of operational performance FY 2024 GAAP to Non-GAAP Reconciliation (In millions, except EPS) | Description | Net Income | Diluted EPS | | :--- | :--- | :--- | | **GAAP** | **$1,289** | **$4.43** | | Intangible amortization | $102 | $0.35 | | Restructuring and other related costs | $76 | $0.26 | | Other adjustments (net) | $72 | $0.25 | | **Non-GAAP** | **$1,539** | **$5.29** | - Non-GAAP adjustments primarily exclude charges for restructuring, asset impairments, intangible amortization, transformational initiatives, and acquisition/integration costs[19](index=19&type=chunk)[34](index=34&type=chunk) [Segment Revenue Reconciliation (Core)](index=14&type=section&id=RECONCILIATION%20OF%20REVENUE%20BY%20SEGMENT%20(CORE)) Segment revenue reconciliation adjusts reported revenue for currency and M&A impacts to present core growth, highlighting underlying business performance Q4 2024 Revenue Growth: Reported vs. Core | Segment | Reported Growth | Core Growth | | :--- | :--- | :--- | | LSAG | -1% | -1% | | DGG | -1% | -3% | | ACG | +5% | +5% | | **Agilent Total** | **+1%** | **0%** | FY 2024 Revenue Growth: Reported vs. Core | Segment | Reported Growth | Core Growth | | :--- | :--- | :--- | | LSAG | -8% | -8% | | DGG | -6% | -6% | | ACG | +5% | +5% | | **Agilent Total** | **-5%** | **-5%** |

Agilent Technologies, Inc. A will release earnings results for the fourth quarter, after the closing bell on Monday, Nov. 25.Analysts expect Agilent to report quarterly earnings at $1.41 per share. That's up from $1.38 per share a year ago. The Santa Clara, California-based company projects to report quarterly revenue of $1.67 billion, compared to $1.69 billion a year earlier, according to data from Benzinga Pro.On Nov. 20, Agilent raised its quarterly dividend to 24.8 cents per share of common stock, a 5% ...

Agilent Technologies (A) is set to report fourth-quarter fiscal 2024 results on Nov. 25.For the fiscal fourth quarter, the company expects revenues of $1.641-$1.691 billion, suggesting a decline of 2.8-0.2% on a reported basis and 1.9-1.1% on a core basis from the year-ago quarter’s actuals.The Zacks Consensus Estimate for revenues is pegged at $1.67 billion, indicating a marginal decline of 0.86% from the year-ago quarter’s reported figure.Agilent’s non-GAAP earnings are expected to be $1.38-$1.42 per shar ...

Earnings Report - Agilent Technologies, Inc. is set to release its fourth-quarter earnings results on November 25, with analysts expecting earnings of $1.41 per share, an increase from $1.38 per share in the same period last year [1] - The company is projected to report quarterly revenue of $1.67 billion, slightly down from $1.69 billion a year earlier [1] Analyst Ratings - Evercore ISI Group analyst Vijay Kumar has maintained an In-Line rating for Agilent and raised the price target from $135 to $145 [2] - The company currently offers an annual dividend yield of 0.75%, translating to a quarterly dividend of 24.8 cents per share [2] Dividend Calculations - To achieve a monthly dividend income of $500, an investor would need to own approximately 6,048 shares of Agilent, equating to a total investment of about $798,699 [3] - For a more conservative monthly income goal of $100, an investor would need to hold 1,210 shares, requiring an investment of around $159,793 [3] Stock Performance - Shares of Agilent increased by 2.7%, closing at $132.06 on Thursday [6]

Agilent Technologies Inc (NYSE:A) is scheduled to release fourth-quarter financial results after the close on Monday, Nov. 25. Analysts expect the medical research name to report earnings of $1.41 per share -- a 2.2% year-over-year increase -- on revenue of $1.67 billion.Looking back on its past eight post-earnings performances, A's history of next-day returns are split, with four positive and four negative. The equity averaged a move of 5.3%, regardless of direction in the last two years, and the options p ...

In its upcoming report, Agilent Technologies (A) is predicted by Wall Street analysts to post quarterly earnings of $1.41 per share, reflecting an increase of 2.2% compared to the same period last year. Revenues are forecasted to be $1.67 billion, representing a year-over-year decrease of 0.9%.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this time ...

Agilent Technologies (A) boosts its LSAG segment with the launch of the Agilent InfinityLab Liquid Chromatography (LC) Series portfolio, comprising the 1290 Infinity III LC, 1260 Infinity III Prime LC and 1260 Infinity III LC systems.The new Agilent InfinityLab Assist Technology is being used for the first time in these High Performance Liquid Chromatography systems, providing enhanced system assistance.These systems have a significant impact on task automation, connectivity, predictive feedback and error r ...